Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Both semaglutide (such as Ozempic) and tirzepatide (such as Zepbound and Mounjaro) belong to a class of medications designed to help manage metabolic disorders, particularly type 2 diabetes.